SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 693.35-0.2%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (882)10/8/2003 12:16:55 PM
From: Icebrg  Read Replies (1) of 3559
 
What struck me as strange was that the participants on 25 mg generally seen seemed to be doing better than those on 50 mg. And that the latter on some of the endpoints had results that were worse than the placebos.

This seems to indicate that their is great variability in the "responses" and indirectly also that maybe the results from the 100 mg group were more due to a fluke than to the drug. More of a "straight-line" dose response would have been more convincing and indicative of a trend.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News